Company Overview and News
U.S. interest rates have shot up to levels not seen in years recently, giving stock investors a new concern. But a Goldman Sachs strategist says it's not time to worry just yet.
Over the last five trading days, banking stocks put up a lackluster show. Though improving U.S. economic data and rising 10-year Treasury bond yields were positives, investors were a bit concerned on the time uncertainty related to the easing of banking regulations and soft loan growth. Nevertheless, strong economy and increasing commodity prices aided a rise in bond yields followed by mortgage rates.
U.S. stocks moved broadly lower in early trading Tuesday, led by declines in technology, health care and consumer-focused companies. The slide put the Dow Jones industrial average on track to end an eight-day winning streak. Bond prices fell, sending yields to the highest level since 2011, after the government reported a solid increase in U.S. retail sales last month.
Encore Capital Group, Inc. (ECPG - Free Report) reported first-quarter 2018 adjusted net income of 98 cents per share, which missed the Zacks Consensus Estimate by 4.8%. However, the bottom line improved 3.2% year over year, driven by a consistently growing supply of charged-off credit card debt and purchase of large amounts of receivables with highest returns.
In 1Q18, Mastercard (MA) reported total gross dollar volumes of $1.41 trillion, which reflects a rise of 14% on a YoY (year-over-year) basis. Of the total gross dollar volumes in 1Q18, the US region contributed $419 billion. In 1Q17, the US region contributed $379 billion. The total gross dollar volumes reflected a 10% rise due to 9% credit growth and 12% debit growth.
May 8 (Reuters) - Capital One Financial Corp said on Tuesday it sold around $17 billion of first and second lien mortgages to DLJ Mortgage, a unit of Credit Suisse.
* CAPITAL ONE ANNOUNCES SALE OF APPROXIMATELY $17 BILLION OF MORTGAGES TO DLJ MORTGAGE CAPITAL, INC., A SUBSIDIARY OF CREDIT SUISSE AG
May 8 (Reuters) - Capital One Financial Corp on Tuesday said it sold around $17 billion of mortgages to a unit of Credit Suisse.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
Fidelity National Information Services’ (FIS - Free Report) first-quarter 2018 adjusted earnings per share from continuing operations came in at $1.09, surpassing the Zacks Consensus Estimate of $1.04. Also, earnings improved 32.9% from the year-ago quarter figure of 82 cents. Shares of Fidelity gained nearly 1% in pre-market trading session, reflecting investors’ optimism on lower expenses and expanding margin in first-quarter results.
Technology giants and big banks have been warily circling each other, especially in the payments arena. So far, they are more frenemies than rivals.
Ally Financial Inc.’s (ALLY - Free Report) first-quarter 2018 adjusted earnings of 68 cents per share surpassed the Zacks Consensus Estimate of 66 cents. Also, the bottom line compared favorably with the prior-year quarter’s figure of 48 cents. Results benefited from an increase in total net revenues and lower provisions. Also, improvement in loans and deposit balances was a positive factor. However, higher expenses witnessed during the reported quarter hurt results to some extent.
Amazon.com, Alibaba Group Holdings, Visa Inc., Apple Inc., and Taiwan Semiconductor Manufacturing are the largest five individual stock positions.
Led by higher spending on its branded cards, Visa Inc. (V - Free Report) reported second-quarter fiscal 2018 (ended Mar 31, 2018) earnings of $1.11 per share, beating the Zacks Consensus Estimate by 9.9%. Also, the bottom line improved 30% year over year.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET